BALTIMORE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, is developing Telomir-1 as the first novel small molecule, to lengthen the DNA’s protective telomere caps in order to affect age reversal, today announced the pricing of its initial public offering of 1,000,000 shares of its common stock at a public offering price of $7.00 per share. All of the shares of common stock are being offered by Telomir. In addition, Telomir has granted the underwriters a 45-day option to purchase up to an additional 150,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Capital Market on February 9, 2024 under the ticker symbol "TELO." The gross proceeds to Telomir from the initial public offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $7 million. The initial public offering is expected to close on February 13, 2024, subject to satisfaction of customary closing conditions.
See the original post here:
Telomir Pharmaceuticals Announces Pricing of Initial Public Offering
